MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE
The present invention relates to a pharmaceutical dosage form for transmucosal delivery of an active agent to two or more mucosal surfaces. The dosage form is presented as a transmucosal delivery device. The devices of the invention may include at least two mucoadhesive surfaces. The devices may further include an intermediate layer disposed between the mucoadhesive layers. The pharmaceutical can be incorporated in any one or all of the mucoadhesive layers or the intermediate layer. Upon application, the device adheres to at least two surfaces, providing transmucosal delivery of the drug to at least two surfaces.
1 . A method of transmucosally delivering an active agent to a subject in need thereof, comprising:
administering to a subject in need thereof a flexible pharmaceutical delivery device wherein the pharmaceutical delivery device comprises:
a first mucoadhesive surface for transmucosal delivery of an active agent;
a second mucoadhesive surface, opposing the first mucoadhesive surface, for transmucosal delivery of an active agent; and
an active agent and an antagonist incorporated into the device,
wherein the first and second mucoadhesive surfaces are defined by one single flexible mucoadhesive film layer; wherein the active agent is an opioid; an effective amount of the active agent is delivered to the subject; and the thickness of the device ranges from about 0.005 mm to about 3 mm.
2 . The method of claim 1 , wherein the device is bioerodable.
3 - 12 . (canceled)
13 . The method of claim 1 , wherein the active agent is buprenorphine.
14 - 16 . (canceled)
17 . The method of claim 1 , wherein the device is administered to a subject by applying the device to a mucosal cavity of the subject such that there is adhesion of the delivery device to at least two surfaces of the mucosal cavity and diffusion of the active agent across the first mucoadhesive surface and the second mucoadhesive surface.
18 . The method of claim 17 , wherein the effective amount of active agent is delivered to the subject in less than about 1 hour.
19 . The method of claim 17 , wherein the effective amount of active agent is delivered to the subject in less than about 30 minutes.
20 . The method of claim 1 , wherein the subject does not experience significant nausea.
21 - 32 . (canceled)
33 . The method of claim 13 , wherein the device contains between about 0.1 mg to about 60 mg of buprenorphine.
34 . The method of claim 33 , wherein T max is less than about 100 minutes.
35 . The method of claim 33 , wherein T max is less than about 80 minutes.
36 . The method of claim 33 , wherein T max is less than about 60 minutes.
37 . The method of claim 33 , wherein T max is less than about 30 minutes.
38 . The method of claim 33 , wherein T max is less than about 20 minutes.
39 . The method of claim 33 , wherein more than 30% of the buprenorphine becomes bioavailable.
40 . The method of claim 33 , wherein more than 50% of the buprenorphine becomes bioavailable.
41 . The method of claim 33 , wherein more than 60% of the buprenorphine becomes bioavailable.
42 . A method of treating addiction, comprising the method of claim 1 .
43 . A method of treating pain, comprising administering an active agent to a subject by the method of claim 1 .
44 . The method of claim 43 , wherein the pain is breakthrough cancer pain.
45 . The method according to claim 1 wherein an effective amount of the active agent is delivered to the subject in one unit dose.